4//SEC Filing
Ginor Ron 4
Accession 0001209191-18-049378
CIK 0001619087other
Filed
Sep 3, 8:00 PM ET
Accepted
Sep 4, 7:42 PM ET
Size
17.6 KB
Accession
0001209191-18-049378
Insider Transaction Report
Form 4
SteadyMed Ltd.STDY
Ginor Ron
Director
Transactions
- Other
Stock Option (Rt to Buy)
2018-08-30−33,350→ 0 totalExercise: $5.60Exp: 2025-08-06→ Ordinary Shares (33,350 underlying) - Sale
Ordinary Shares
2018-08-30$4.46/sh−1,045,816$4,664,339→ 0 total(indirect: See Footnote.) - Sale
Ordinary Shares
2018-08-30$4.46/sh−105,306$469,665→ 0 total(indirect: See Footnote) - Other
Stock Option (Rt to Buy)
2018-08-30−3,875→ 0 totalExercise: $3.85Exp: 2026-10-03→ Ordinary Shares (3,875 underlying) - Other
Stock Options (Rt to Buy)
2018-08-30−21,029→ 0 totalExercise: $3.65Exp: 2025-12-28→ Ordinary Shares (21,029 underlying) - Sale
Ordinary Shares
2018-08-30$4.46/sh−16,298$72,689→ 0 total(indirect: See Footnote)
Footnotes (6)
- [F1]Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). Under the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding ordinary share of the Issuer was converted into the right to receive (1) $4.46 in cash plus (2) one contractual contingent value right (a "CVR"), which represents the right to receive $2.63 in cash upon the achievement of a specified milestone (the "Milestone").
- [F2]By Samson Venture Partners I, LLC. Samson Venture Partners, LLC is the Manager and the Reporting Person is a Co-Manager of Samson Venture Partners, LLC.
- [F3]By Iron Capital I, LLC. Iron Capital, LLC is the Manager and the Reporting Person is the Sole Manager of Iron Capital, LLC.
- [F4]By Randsburg Capital, LLC. Reporting Person is a Co-Manager of Randsburg Capital, LLC.
- [F5]Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding out-of-the-money option, whether vested or unvested, was converted into the right to receive a cash payment, if and when the Milestone is achieved, equal to (x) the excess, if any, of the sum of (1) $4.46 and (2) the contingent consideration actually payable per CVR over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time.
- [F6]Disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2018, by and among United Therapeutics Corporation ("United"), Daniel 24043 Acquisition Corp., a wholly-owned subsidiary of United, and the Issuer (the "Merger Agreement"). At the Effective Time, each outstanding in-the-money option, whether vested or unvested, was converted into the right to receive (1) a cash payment equal to (x) the excess, if any, of $4.46 over the exercise price payable under such option, multiplied by (y) the total number of shares subject to such option immediately prior to the Effective Time and (2) a number of CVRs equal to the total number of shares subject to such option immediately prior to the Effective Time.
Documents
Issuer
SteadyMed Ltd.
CIK 0001619087
Entity typeother
Related Parties
1- filerCIK 0001637070
Filing Metadata
- Form type
- 4
- Filed
- Sep 3, 8:00 PM ET
- Accepted
- Sep 4, 7:42 PM ET
- Size
- 17.6 KB